NCT06497595Recruiting
Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
Exercise and Nutritional Intervention to Reduce the Risk of Sarcopenia in Older Adults With Type 2 Diabetes and Obesity Treated With Semaglutide: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65 and above) with Type 2 diabetes (T2D) and obesity treated with Semaglutide. The main questions it aims to answer are: In older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations: 1. Reduce the rate of decline in muscle mass? 2. Reduce the rate of decline in muscle strength? 3. Reduce the rate of decline in physical function? Participants will: Administer Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 27 Jun 2024
- Start date
- 11 May 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Sheba Medical Center
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06497595
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 11 May 2025 to the primary completion date, 30 Sept 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are in active nutritional therapy.
- Patients who changed their diet recently (\< 1 month) and/or in a weight-loss program with \>5% weight loss or used anti-obesity drugs in the last 3 months.
- Patients who are currently using systemic steroids.
Other illness
- Patients with musculoskeletal disorders, which, by the judgment of the investigators, would limit their ability to perform the exercise training.
- Patients with neurological diseases, which by the judgment of the investigators, would affect their ability to participate in the trial.
- Patients with a history of amputation that impairs their ability to participate in the exercise program.
- Patients with active oncological diseases, excluding non-melanoma skin cancer.
- Patients with diagnosed dementia or cognitive impairment that, in the view of the researchers, may impair their ability to sign a consent form or participate in the trial.
- Any contraindication to Magnetic resonance imaging (MRI) (e.g., MRI non-compatible cardiac implantable electronic device, metallic foreign bodies, implantable neurostimulation system, cochlear implants/ear implant, non-removable drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips which), or inability to perform an MRI scanner (e.g., claustrophobia).
Lab values
- Patients with Estimated Glomerular Filtration Rate (eGFR)\<30 ml/min/1.73 m2.
Other
- Patients with significant hearing or visual disability.
- Patients who reported a weight loss of \>5kg within 90 days of screening
- Patients who were on Glucagon-like peptide-1 receptor agonists (GLP-1-RA) treatment during the last 3 months.
- Patients with disabilities, which, by the judgment of the investigators, would affect their ability to participate in the trial.
- Patients who use a walking aid.
- Patients who were hospitalized in the past month.
- Patients who exercise regularly and in the eyes of the examiner will not benefit from the intervention program.
- Anyone who is not suitable to participate in the study, according to the researcher's discretion.
- Patients who do not fit within the measurement field of view of the Dual-energy X-ray absorptiometry (DXA) scanner in a supine position with the arms next to the body.
Who the study is looking for
- Patients 65 years and above.
- Patients who were previously diagnosed with type 2 diabetes.
- Overweight / obesity (body mass index, BMI ≥ 27 kg/m2).
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hadassah medical Center Coordinator of this site? Confirm its status | Jerusalem | Israel | Not yet recruiting |
| Sheba medical center Coordinator of this site? Confirm its status | Ramat Gan | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.